Kymera Therapeutics (KYMR) Stock Forecast & Price Target
Score
Kymera Therapeutics, Inc. price target
| KYMR | |
|---|---|
| Low | $115.00 |
| Average | $141.53 |
| High | $180.00 |
| Upside vs current price | +5.0% |
The average target of $141.53 is +5.0% versus the current KYMR price of $134.84.
Kymera Therapeutics, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 5 |
| Buy | 17 |
| Hold | 2 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
24 analysts cover KYMR.
Kymera Therapeutics, Inc. EPS and revenue estimates
Published annual figures for KYMR on this page are 2026 EPS $-3.95, 2027 EPS $-5.13. Coverage under three analysts is omitted.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-3.95 | $100.48M |
| 2027 | $-5.13 | $42.03M |
Is Kymera Therapeutics, Inc. a buy or sell?
Of the 24 analysts covering Kymera Therapeutics, Inc., 22 rate it a buy (5 strong buy and 17 buy), 2 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The KYMR consensus label is Buy, beside 22 buy-side ratings and 0 sell-side ratings.
The average target of $141.53 implies +5.0% versus the current price of $134.84.
The KYMR rating block is 24 published views with a Buy label. It does not tell you whether to buy or sell.
Reading the Kymera Therapeutics, Inc. forecast
A wide spread is the story on KYMR. Targets run from $115.00 to $180.00, with $141.53 as the average.
The gap from the $134.84 price to the KYMR average is +5.0%.
The KYMR rating mix is lopsided rather than split: 22 of 24 analysts are on the buy side, 2 are at hold, and 0 are on the sell side, and the published consensus is Buy.
The latest KYMR actions do not point one way: 1 up and 0 down.
The recent KYMR average ($137.33) is under the quarterly figure ($145.30).
the Kymera Therapeutics, Inc. is followed by 24 analysts, so the range matters more than any one target.
Kymera Therapeutics, Inc. forecast questions
What is the KYMR price target?
The published range for KYMR is $115.00 to $180.00, with an average of $141.53. That average is +5.0% versus the current price of $134.84.
Is Kymera Therapeutics, Inc. a buy or sell?
Of the 24 analysts covering Kymera Therapeutics, Inc., 22 rate it a buy, 2 rate it a hold, and 0 rate it a sell. The consensus is Buy, leaving KYMR at 22 buy ratings, 2 holds, and 0 sells.
What is the EPS estimate for Kymera Therapeutics, Inc.?
Analyst EPS estimates for Kymera Therapeutics, Inc.: 2026 $-3.95, 2027 $-5.13.
What is the revenue estimate for Kymera Therapeutics, Inc.?
Analyst revenue estimates for Kymera Therapeutics, Inc.: 2026 $100.48M, 2027 $42.03M.
How many analysts cover KYMR?
24 analysts cover KYMR. Their consensus on KYMR is Buy, across those 24.